Physician profile
Tanushree Bhatt
NPI 1831761071
$1,421.57
in general payments reported to CMS, 2019-2025
11 companies · $739 in 2025
The $739 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $683 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $823 · Food and Beverage: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $822.82 |
| Food and Beverage | $598.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $260.10 | 2024-2025 | |
| Incyte Corporation | $242.01 | 2024-2025 | Jakafi, Niktimvo |
| Lilly USA, LLC | $201.97 | 2025 | |
| Exelixis INC. | $194.69 | 2024-2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $175.94 | 2024-2025 | Soliris |
| Jazz Pharmaceuticals INC. | $143.43 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $95.99 | 2025 | |
| Genzyme Corporation | $44.94 | 2024-2025 | |
| Syndax Pharmaceuticals, INC. | $23.81 | 2025 | |
| Pharmacosmos Therapeutics INC. | $19.73 | 2024 | Monoferric |
| Astrazeneca Pharmaceuticals LP | $18.96 | 2024 | Tagrisso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanushree Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.